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Purpose: Single nucleotide polymorphisms (SNPs) in the tightly linked LOC387715/ARMS2 and HTRA1 genes have been
associated with age-related macular degeneration (AMD). We tested whether these SNPs are associated with AMD in
Israeli populations, if they underlie variable phenotype and response to therapy in neovascular AMD (NVAMD), and if
HTRA1 expression in vivo is associated with its promoter variant.
Methods: Genotyping for the rs10490924 SNP in LOC387715/ARMS2 and the rs11200638 SNP in HTRA1 was performed
on 255 NVAMD patients and 119 unaffected controls from Ashkenazi and Sephardic Jewish, and from Arab origins which
are the main ethnic groups composing the Israeli population. Genotyping was correlated with phenotype and response to
therapy among 143 patients who underwent photodynamic therapy (PDT). HTRA1 mRNA levels in white blood cells
(WBCs), measured by quantitative PCR, were correlated with genotype in 27 participants.
Results: Both SNPs were in almost complete linkage disequilibrium (D'=0.96–1). Homozygotes for the T allele of
rs10490924 had an odds ratio (OR) of 8.6, with a 95% confidence interval (CI) of 3.5–20.8, and homozygotes for the A
allele of rs11200638 had an OR of 10.7, with a 95% CI of 3.2–35.7, for having AMD (p<0.00001). There was no association
among these SNPs and phenotype or response to PDT. HTRA1 mRNA levels in WBCs were not associated with
rs11200638 genotypes.
Conclusions: The rs10490924 SNP in LOC387715/ARMS2 and the rs11200638 SNP in HTRA1 are strongly associated
with NVAMD in this Israeli population. These variants do not have a major contribution to the variable phenotype and
response to PDT which characterize NVAMD.
Single  nucleotide  polymorphisms  (SNPs)  in
chromosome 10q26 are associated with the risk for having
age-related  macular  degeneration  (AMD)  in  several
populations [1-18]. Since several 10q26 SNPs are associated
with disease risk, it has been difficult to determine if the T
allele  of  rs10490924  located  in  the  coding  region  of  the
LOC387715/ARMS2 (age-related maculopathy susceptibility
2) gene, or the A allele of rs11200638 located in the promoter
region of high-temperature requirement factor A1 (HTRA1)
have a role in the pathogenesis of the disease [6-9,13,19].
The HTRA1 gene encodes a heat shock serine protease
which is expressed in the retina and can regulate transforming
growth  factor-β  (TGF-β)  signaling  [7,20].  Evidence  has
conflicted with respect to the correlation between rs11200638
genotypes and HTRA1 expression levels [6-8].
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The LOC387715/ARMS2 gene encodes a putative 12 kDa
protein. Although it has been suggested that LOC387715/
ARMS2 may not actually encode a protein, recent data has
shown that it encodes a mitochondrial outer membrane protein
that  is  also  expressed  in  the  retina  [6].  The  T  allele  of
rs10490924 changes amino acid 69 from alanine to serine
(A69S variant) in the putative LOC387715/ARMS2 protein
[6,13].  Fritsche  [21]  and  colleagues  recently  described  a
related variant in this gene that is associated with AMD and
results in rapid mRNA turnover and undetectable expression
levels in homozygous carriers.
Neovascular AMD (NVAMD) shows variable phenotype
in  terms  of  several  parameters,  including  age  of  onset,
neovascular lesion type and size, and response to treatment.
Efforts are underway to identify genetic and other biomarkers
that  correlate  with  these  various  disease  parameters.  Of
particular  interest  would  be  the  identification  of
pharmacogenetic  markers  that  might  be  able  to  predict
response to therapy, since such information could potentially
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2263be used to guide choice, and perhaps frequency, of treatment
for the individual patient. Recently, a genetic variant in the
complement  factor  H  (CFH)  gene,  which  is  strongly
associated with AMD, has been reported to be associated with
neovascular lesion type, size, and response to photodynamic
therapy (PDT) and injections of the antivascular endothelial
growth factor compound bevacizumab [22-26]. The HTRA1
polymorphism was associated with classic lesion type [26].
However,  similar  associations  have  not  been  consistently
found in other populations [10,27,28].
To test the association of the 10q26 SNPs with NVAMD
in Israeli populations and to expand our knowledge about
phenotype-genotype correlation, we first evaluated HTRA1
and LOC387715/ARMS2 polymorphisms and NVAMD risk
in  Israel.  The  study  included  Arabs,  Sephardic  Jews,  and
Ashkenazi Jews which are the main ethnic groups composing
the Israeli population. After finding a significant association,
similar in magnitude to that reported in other populations, we
assessed if these SNPs could account for some of the observed
variation  in  clinical  characteristics  and  response  to  PDT
among the NVAMD patients. Finally, as another approach to
explore whether the SNP in the 5′-upsteam region of the
HTRA1 promoter influences promoter activity, we tested to
see if there was a correlation between genotype and HTRA1
mRNA levels in vivo as measured in the white blood cells
(WBCs) of patients and controls.
METHODS
Patients and genotyping: The study included 255 NVAMD
patients recruited from four retina clinics in Israel and 119
unaffected controls (from the department of Ophthalmology)
who  were  evaluated  for  routine  eye  examination  or  for
pathologies  other  than  AMD,  in  the  Department  of
Ophthalmology  of  the  Hadassah  –  Hebrew  University
Medical  Center  in  Jerusalem,  Israel.  Institutional  Ethics
Committee approval was obtained for the study, and each
patient  signed  an  informed  consent  form.  AMD  was
diagnosed and graded according to the age related eye disease
study (AREDS) trial classification [29]. Inclusion criteria for
the control group included age over 60 years, clear cornea,
lens,  and  vitreous  which  enabled  ophthalmoscopy,  and
absence of intermediate size drusen, multiple small drusen, or
retinal  pigment  epithelial  abnormalities  characteristics  of
AMD (AREDS category I). The data set was described in a
manuscript evaluating CFH variants in the Israeli population
[30]. Briefly, female:male ratio was balanced between AMD
patients and controls. Mean age in the controls (70.8±8.2) was
lower than that of AMD patients (78.1±7.6; p<0.05, unpaired,
two-sided,  t-test).  Median  follow-up  of  NVAMD  patients
having PDT was 16 months (range 1–156 months).
WBCs  were  separated  from  blood  samples  from  27
individuals included in the genotyping study (22 NVAMD
patients and 5 unaffected controls). These samples were used
for RNA extraction. For WBC separation, 4 CC of whole
blood were drawn and shipped to the laboratory on wet ice.
RNA was then extracted as described below.
The  Israeli  population  is  composed  of  several  ethnic
groups, which include Ashkenazi Jews, Sephardic Jews, and
Arabs.  Studies  showed  that  these  subpopulations  may  be
genetically  defined,  for  example,  by  polymorphisms  and
microsatellite loci on the Y chromosome [31]. Intermarriage
between the groups was uncommon among parents of the
elderly individuals included in the study. The control group
included 10 Arabs, 40 Sephardic Jews, and 68 Ashkenazi
Jews, while the study group included 11 Arabs, 75 Sephardic
Jews, and 163 Ashkenazi Jews (p=0.13, χ2 test). The ethnicity
of one individual from the control group and 6 NVAMD
patients was unknown.
Genotyping  for  the  rs11200638  SNP  in  the  putative
promoter region of HTRA1 and for the rs10490924 SNP in the
coding  region  of  the  LOC387715/ARMS2  gene  was
performed.  This  was  done  by  sequencing  PCR  products
containing these SNPs (Table 1).
Detailed retrospective clinical information was available
on a subgroup of 143 sequential NVAMD patients (of the 255
patients enrolled in the study) who were treated with PDT at
the  Hadassah–Hebrew  University  Medical  Center.  These
patients were included in the phenotype-genotype analysis
and for the purpose of analysis eyes of these patients which
underwent PDT were considered as the study eye. Fluorescein
angiograms were reviewed by retina specialists (I.C., E.B.,
I.H., and E.A.) who were masked with respect to genotype
results; choroidal neovascularization was classified as classic,
predominantly classic, minimally classic, or occult following
the guidelines of the Macular Photocoagulation Study Group
[32]. Retinal angiomatous proliferation (RAP) was classified
as occult lesions. Review of the entire group of patients was
also performed in a masked fashion (with respect to previous
lesion type classifications and to genotypes) by one of the
investigators (I.C.). There was agreement in 83.4% of cases
between this investigator and the classification by the treating
retina  specialist  (kappa  measurement  of  agreement=0.68,
p<0.0001).  Classification  of  lesion  type  according  to  the
TABLE 1. PRIMERS USED FOR GENOTYPING AND QPCR.
Primer Sequence
Primers for genotyping
LOC387715/ARMS2 forward TACCCAGGACCGATGGTAAC
LOC387715/ARMS2 reverse GAGGAAGGCTGAATTGCCTA
HTRA1 forward CGGATGCACCAAAGATTCTCC
HTRA1 reverse TTCGCGTCCTTCAAACTAATGG
Primers for QPCR
HTRA1 forward AGCTGGGACTTCGGAACTCC
HTRA1 reverse TCCGGAATTTCCATAATTGATGA
GAPDH forward GGGGGAGCCAAAAGG GTCAT
GAPDH reverse GCCCCAGCGTCAAAGGTGGA
Sequence  of  primers  which  were  used  for  genotyping  of
LOC387715/ARMS2   (rs10490924)  and  HTRA1
(rs11200638) SNPs and for QPCR for assessment of HTRA1
mRNA levels.
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for  statistical  analysis.  The  standard  PDT  protocol  for
NVAMD was applied [33]. Briefly, patients received 6 mg/
m2  body  surface  area  of  verteporfin  (Visudyne;  Novartis
Ophthalmics, Hettlingen, Switzerland) intravenously over 10
min.  Fifteen  min  after  commencement  of  the  infusion
exposure  of  50  J/cm2  was  applied  at  the  radiant  level  of
600 mW/cm2 over 83 s using a diode laser (Visulas s 690,
Zeiss, Switzerland), and the PDT laser lens (Volk, Mentor,
OH).
The association between smoking and the risk for having
NVAMD,  and  its  interaction  with  the  10q26  SNPs  was
analyzed. Individuals were considered as smokers if they were
smoking at the time of the study or if they smoked in the past.
Individuals  who  never  smoked  were  considered  as  non-
smokers.
Quantitative real-time RT–PCR: HTRA1 mRNA levels were
measured  in  WBCs  from  27  participants  (22  NVAMD
patients and 5 unaffected controls older than 60 years of age).
WBCs were separated from whole blood using hypotonic lysis
buffer containing 155 mM NH4Cl (Gadot, Or Akiva, Israel),
10 mM CH2O3·NH3 (Sigma-Aldrich, St. Louis, MO), and
0.1 mM EDTA (pH 7.4; J.T. Baker, Philipsberg, NJ). Next,
8 ml of buffer was added to 4 ml of blood, which was then
stored on ice for 10 min and centrifuged at 2,000x g at 4 °C
for 10 min. Supernatant was discarded and the sequence was
repeated an additional time. The WBC pellet was resuspended
in 1 ml of TRI Reagent (Sigma). RNA was then extracted
followed  by  treatment  with  DNase  (DNAfree;  Ambion,
TABLE 2. FREQUENCY OF LOC387715/ARMS2 (RS10490924) ALLELES AND GENOTYPES IN NVAMD PATIENTS AND UNAFFECTED
CONTROLS.
LOC387715/ARMS2
 (rs10490924
AMD Unaffected p
OR
(95% CI)
By allele
Entire population
(G/T; %)*
279/219
(56/44)
190/48
(80/20)
<0.0001 3.1 (2.2–4.5)
Ashkenazi Jews 189/129
(59.4/40.6)
110/26
(80.8/19.2)
<0.0001 2.9 (1.8–4.7)
Sephardic Jews 76/72
(51.4/48.6)
63/17
(78.8/21.2)
<0.0001 3.5 (1.9–6.6)
Arabs 8/12
(40/60)
16/4
(80/20)
0.022 6 (1.5–24.7)
By genotype
Entire Population     <0.0001
          GG (%) 91 (36.5) 77 (64.2)  
          TG (%) 97 (39) 36 (30.3) 0.0012 2.3 (1.4–3.7)
          TT (%) 61 (24) 6 (5) <0.0001 8.6 (3.5–20.8)
Ashkenazi Jews     <0.0001
          GG (%) 67 (42.1) 45 (66.2)  
          TG (%) 55 (34.6) 20 (29.4) 0.17 1.6 (3.1–0.82)
          TT (%) 37 (23.3) 3 (4.4) 0.003 9.7 (41.6–2.2)
Sephardic Jews     0.0003
          GG (%) 20 (27) 26 (65)  
          TG (%) 36 (48.6) 11 (27.5) 0.003 4.3 (10.4–1.7)
          TT (%) 18 (24.3) 3 (7.5) 0.001 7.8 (30.3–2)
Arabs#     0.036
          GG (%) 3 (30) 6 (60)  
          TG (%) 2 (20) 4 (40)  
          TT (%) 5 (50) 0 (0)  
Comparison of the frequency (%) of the LOC387715/ARMS2 (rs10490924) variant between NVAMD patients and controls in
the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the T variant
was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI-
confidence interval, OR- odds ratio. The asterisk indicates reliable genotyping for rs10490924 was obtained from 249 of the
255 patients and for each of the 119 controls. The hash mark represents there were too few Arabs to obtain reliable ORs and
CIs for analysis of genotypes in this sub population.
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)Austin, TX), and cDNA was synthesized from 1 ug of total
RNA using the Reverse iT 1st Strand Synthesis Kit (ABgene,
Epsom, UK) and oligo dT primers. Quantitative real-time RT–
PCR (QPCR) was performed with HTRA1 specific primers
(Table 1) using the ABI Prism 7000 SDS instrument (Applied
Biosystems,  Foster  City,  CA).  Measurements  of  GAPDH
were  used  for  normalization  of  expression  levels  across
samples.
Statistical  analysis:  Statistical  analysis  and  power
calculations were performed using SPSS (SPSS, Chicago, IL)
and Instat software (GraphPad, San Diego, CA) as we have
previously described [30]. Briefly, logistic regression and χ2
tests were applied to assess odds ratios, confidence intervals,
and significance. Linkage disequilibrium was assessed by D’
calculation. Based on the number of individuals included in
the analysis this study had 85% power for identification of an
association  between  genotypes  and  lesion  type  in  the
magnitude described by Brantley and colleagues [22]. The
study also had 94% power for identification of an association
between genotypes and visual acuity following PDT in the
magnitude, which was described by the same group [25].
RESULTS
Association of 10q26 SNPs with NVAMD: Both the HTRA1
rs11200638 SNP and the LOC387715/ARMS2 rs10490924
SNP complied with Hardy–Weinberg equilibrium. Genotypes
for  both  SNPs  were  in  almost  complete  linkage
disequilibrium, with D' values of 1.00 for NVAMD patients
and 0.96 for controls. Distribution of the genotypes for both
SNPs was significantly different between NVAMD patients
and controls (p<0.0001; Table 2 and Table 3).
Homozygotes  for  the  T  allele  of  rs10490924
(LOC387715/ARMS2) had an odds ratio (OR) of 8.6 with a
95%  confidence  interval  (CI)  of  3.5–20.8,  while
TABLE 3. FREQUENCY OF HTRA1 (RS11200638) ALLELES AND GENOTYPES IN NVAMD PATIENTS AND UNAFFECTED CONTROLS
HTRA1
(rs1200638) AMD Unaffected p
    OR
(95% CI)
By allele
Entire population (G/A; %) 325/185
(63.7/36.3)
197/41
(82.8/17.2)
<0.0001 2.7 (1.9–4)
Ashkenazi Jews 212/114
(65/35)
114/22
(83.8/16.2)
<0.0001 2.8 (1.7–4.6)
Sephardic Jews 95/55
(63/37)
65/15
(81.3/18.7)
0.0065 2.5 (1.3–4.8)
Arabs 10/12
(45.4/54.6)
17/3
(0.85/0.15)
0.01 6.8 (1.5–30.1)
By genotype
Entire population     <0.0001
          GG (%) 116 (45.5) 81 (68.1)  
          GA (%) 93 (36.5) 35 (29.4) 0.013 1.8 (1.1–3.0)
          AA (%) 46 (18.0) 3 (2.5) <0.0001 10.7 (3.2–35.7)
Ashkenazi Jews     0.011
          GG (%) 80 (49.1) 48 (70.6)  
          GA (%) 52 (31.9) 18 (26.5) 0.24 1.5 (3–0.76)
          AA (%) 31 (19) 2 (2.9) 0.009 7.2 (31.2–1.6)
Sephardic Jews     0.02
          GG (%) 30 (40) 26 (65)  
          GA (%) 35 (46.7) 13 (32.5) 0.044 2.3 (5.3–1.02)
          AA (%) 10 (13.3) 1 (2.5) 0.046 8.7 (71.5–1.04)
Arabs#     0.05
          GG (%) 4 (36.4) 7 (70)  
          GA (%) 2 (18.1) 3 (30)  
          AA (%) 5 (45.5) 0 (0)  
Comparison of the frequency (%) of the HTRA1 (rs11200638) variant between NVAMD patients and controls in the entire
Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the A variant was
associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence
interval, OR- odds ratio. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of
genotypes in this sub population.
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NVAMD compared with homozygotes for the wild-type allele
(Table  2).  Combined,  individuals  either  homozygous  or
heterozygous for the T allele had an OR of 3.2 (95% CI of 2–
5; p<0.0001) compared with individuals homozygous for the
G  allele  for  having  AMD.  Analysis  according  to  allele
distribution showed similar findings to analysis according to
genotypes for each of the SNPs (Table 2).
Homozygotes for the A allele of rs11200638 had an OR
of 10.7 (95% CI of 3.2–35.7), while heterozygotes had an OR
of 1.8 (95% CI of 1.1–3) for having NVAMD compared with
homozygotes for the wild-type allele (Table 3). Combined,
individuals  either  homozygous  or  heterozygous  for  the  A
allele had an OR of 2.5 (95% CI of 1.6–4; p<0.0001) compared
with  individuals  homozygous  for  the  G  allele  for  having
AMD.
Subgroup  analysis  was  performed  to  evaluate  for
association of both SNPs with NVAMD among Ashkenazi
Jews,  Sephardic  Jews,  and  Arabs.  The  rs10490924
(LOC387715/ARMS2)  SNP  was  associated  with  NVAMD
among Ashkenazi Jews (p<0.0001, χ2 test), Sephardic Jews
(p=0.0003,  chi-square  test),  and  Arabs  (p=0.036,  χ2  test).
Analysis  according  to  allele  distribution  showed  similar
findings (Table 2). The rs11200638 (HTRA1) SNP was also
associated with NVAMD among Ashkenazi Jews (p=0.011,
χ2 test), Sephardic Jews (p=0.044, χ2 test), and Arabs (p=0.05,
χ2  test).  Analysis  according  to  allele  distribution  showed
similar findings (Table 3).
Smoking is an established risk factor for AMD. Since this
risk factor was also associated with chromosome 10q26 SNPs
in  other  populations  [11],  we  evaluated  its  effect  in  our
population. Smoking was associated with the risk for having
AMD (OR of 3; 95% CI of 1.7–5.3; p<0.001) in the entire
population; however, logistic regression found no interactions
between  smoking  and  either  homozygosity  (p=0.359)  or
heterozygosity for the risk allele of rs10490924. There were
also  no  interactions  between  smoking  and  either
homozygosity (p=0.99) or heterozygosity (p=0.29) for the risk
allele of rs11200638.
Association  of  10q26  SNPs  with  phenotype  of  NVAMD:
Following  the  establishment  of  an  association  among  the
HTRA1  rs11200638  SNP,  the  LOC387715/ARMS2
rs10490924 SNP, and NVAMD in the Israeli population, we
explored  possible  correlations  between  the  genotypes  and
clinical characteristics of NVAMD and response to PDT. This
analysis included 143 sequential NVAMD patients who were
treated in the Department of Ophthalmology of the Hadassah
Medical  Center  and  who  were  characterized  in  terms  of
phenotype  and  response  to  PDT.  Reliable  genotyping  for
rs11200638 was obtained from all of these participants and for
rs10490924 from 139 of these patients.
There was no significant association between these SNPs
and gender, history of smoking, lesion type, initial and final
visual acuity, and number of PDT sessions required. The T
allele of rs10490924 was associated with a positive family
history for AMD while the A allele of rs11200638 showed a
trend toward such an association (Table 4 and Table 5). While
23.7% of individuals carrying at least one risk allele (A) of
rs11200638 had a positive family history for AMD, only 8.6%
of the individuals homozygous to the wild-type allele had a
positive family history (p=0.043, χ2 test). However, this p
value  would  lose  significance  if  any  form  of  multiple
hypothesis testing correction was applied. Similarly, while
22.8% of individuals carrying at least one risk allele (T) of
rs10490924 had positive family history for AMD, only 4.4%
of the individuals homozygous for the wild-type allele had a
positive family history (p=0.008, chi square test). The risk
alleles of both SNPs showed a trend toward an association
with younger age of onset of NVAMD and with larger lesion
size (Table 4 and 5).
mRNA levels of HTRA1 in WBCs from NVAMD patients:
mRNA  levels  of  HTRA1  were  measured  using  QPCR  in
WBCs from 22 NVAMD patients and 5 unaffected controls
to assess the effect of the HTRA1 promoter variant on HTRA1
expression. ANOVA showed no significant differences in
HTRA1  mRNA  levels  among  individuals  with  different
rs11200638 genotypes (Figure 1A), and between patients and
controls (Figure 1B). HTRA1 expression levels were similar
in homozygote of the A allele and homozygote of the G allele
(p=0.2).
DISCUSSION
This study established an association between the A allele of
rs11200638,  located  in  the  putative  promoter  region  of
HTRA1,  and  the  T  allele  of  rs10490924  (A69S  variant),
located  in  the  coding  region  of  LOC387715/ARMS2,  and
NVAMD in the Israeli population. Both SNPs are strongly
associated with NVAMD among Ashkenazi and Sephardic
Jews. While NVAMD is relatively uncommon among Arabs
in Israel [34], our data suggest that 10q26 SNPs are also
associated  with  NVAMD  in  this  ethnic  group.  Similar  to
findings  from  fair-skinned  populations  and  Japanese
populations,  these  SNPs  are  in  almost  complete  linkage
disequilibrium in the Israeli populations [1,7,8].
Increased  prevalence  of  the  same  HTRA1  and
LOC387715/ARMS2  variants  among  AMD  patients  was
described in several fair-skinned populations as well as in
cohorts from India, Japan, and China [1-8,21,35-39]. The
magnitude  of  the  association  between  these  SNPs  and
NVAMD in Israel is similar to the one which was reported in
other populations. For example, Rivera and colleagues [13]
found an OR of 2.7 for AMD patients who were heterozygous
for the LOC387715/ARMS2 A69S variant and an OR of 8.2
for  patients  who  were  homozygous  for  it  .  In  the  Israeli
population  participants  who  were  heterozygous  for  this
variant had an OR of 2.3 while those homozygous for it had
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SNPs with neovascular AMD compared with dry AMD was
suggested by previous studies [2,9,40]. As our study focused
on  NVAMD  patients,  we  were  not  able  to  evaluate  for
differences in the magnitude of the association between the
HTRA1 and LOC387715/ARMS2 variants and the dry and
neovascular forms of AMD.
This  study  also  evaluated  if  variable  phenotype  and
response  to  therapy  among  NVAMD  patients  may  be
attributable  to  the  chromosome  10q26  SNPs.  The
LOC387715/ARMS2  A69S  variant  was  associated  with
younger age of examination for AMD, but not with other
phenotypic characteristics of NVAMD in a recent study [40].
In accordance with that, a trend toward younger age of onset
of  NVAMD  was  associated  with  both  the  HTRA1  and
LOC387715/ARMS2  variants  in  our  study.  Another
observation  suggesting  an  aggressive  phenotype  in
association with the LOC387715/ARMS2 variant was reported
by Brantley and colleagues [10] who proposed that this variant
is associated with larger neovascular lesions. A trend toward
TABLE 4. CORRELATION AMONG DEMOGRAPHIC AND PHENOTYPIC CHARACTERISTICS OF NVAMD AND GENOTYPING FOR LOC387715/ARMS2
(RS10490924).
LOC387715/ARMS2 (rs10490924) genotype
TT TG GG p
Gender (female/male) 21/14 24/27 20/33 0.12
Lesion type* (classic/occult) 11/24 23/28 19/34 0.4
Family History of AMD (yes/no) # 9/19 7/35 2/43 0.006
Age (mean±SD, in years) 76.4±8 78.9±8.5 80.1±7.2 0.1
Smoking (yes/no) # 12/20 25/25 27/25 0.42
Initial VA (mean±SD, logMAR) 1.06±0.83 0.94±0.68 1.14±0.79 0.44
Lesion size (mean±SD, in µm) 4081±1347 3669±1265 3623±1288 0.34
Number of PDT sessions 2.2±2.2 2.6±1.9 2±1.6 0.22
Final VA (mean±SD, logMAR) 1.5±0.9 1.51±0.83 1.37±0.93 0.67
The asterisk indicates that classic lesions included predominantly classic and pure classic lesions. Occult lesions included
minimally  classic and occult lesions. Analysis according to four lesion types showed similar results. # Reliable information on
family history was obtained from 117 out of the 143 participants included in this analysis, and smoking history was obtained
from 138 of the 143 study participants.
TABLE 5. CORRELATION AMONG DEMOGRAPHIC AND PHENOTYPIC CHARACTERISTICS OF NVAMD AND GENOTYPING FOR HTRA1
(RS11200638)
HTRA1 (rs11200638) genotype
AA GA GG p
Gender (female/male) 14/10 25/25 29/40 0.35
Lesion type* (classic/occult) 7/17 22/28 26/43 0.46
Family History of AMD (yes/no) # 5/14 9/31 5/53 0.08
Age (mean ± SD, in years) 75.6±7 79.2±8.5 79.5±7.8 0.1
Smoking (yes/no) # 11/12 22/26 33/34 0.93
Initial VA (mean ± SD, logMAR) 1.1±0.8 0.928±0.7 1.1±0.8 0.38
Lesion size (mean ± SD, in µm) 4250±1261 3696±1290 3603±1261 0.17
Number of PDT sessions 2.5±1.9 2.4±1.8 2.2±1.9 0.78
Final VA (mean ± SD, logMAR) 1.6±0.84 1.5±0.84 1.36±0.94 0.45
The asterisk indicates classic lesions included predominantly classic and pure classic lesions. Occult lesions included minimally
classic  and occult lesions. Analysis according to four lesion types showed similar results. # Reliable information on family
history was obtained from 117 out of the 143 participants included in this analysis, and smoking history was obtained from 138
of the 143 study participants.
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variants with larger neovascular lesions was also observed in
this study. While association of the HTRA1 variant with the
classic  lesion  type  was  described  in  a  French  population
[26],  such  association  was  not  identified  in  another  fair-
skinned population which was evaluated [10] or in the Israeli
population.
Brantley  and  coworkers  did  not  find  an  association
between LOC387715/ARMS2 A69S variant and response to
bevacizumab injections in 86 patients. The same group did not
find an association between this variant and response to PDT
in 69 patients [10,25]. Yet, these authors found an association
between response to bevacizumab injections and the CFH
Y402H polymorphism. We confirmed this observation with
respect to the LOC387715/ARMS2 variant and expanded it to
include the HTRA1 variant in 143 Israeli NVAMD patients.
Both variants were not associated with the visual outcome or
with the number of PDT sessions required. Combined, these
data do not support the existence of a major pharmacogenetic
Figure 1. Relative expression levels of HTRA1 in NVAMD patients
and unaffected controls. A: Shown are expression levels in white
blood  cells  according  to  rs11200638  genotypes  in  individuals
homozygous  for  the  wild-type  allele  (GG,  n=13),  participants
homozygous  for  the  risk  allele  (AA,  n=6),  and  in  heterozygous
participants (AG, n=8). Differences between the three groups were
not significant (p>0.1 for each comparison). B: Shown are mRNA
levels of HTRA1 in 22 NVAMD patients and 5 unaffected individuals
(p=0.9). In both A and B, RQ represents relative HTRA1 mRNA
levels. Error bars represent standard deviation (SD).
interactions  among  chromosome  10q26  SNPs  and  current
therapies for NVAMD.
It is still unclear if the HTRA1 variant or the LOC387715/
ARMS2 variant has a causative role in the pathogenesis of
AMD. While Dewan and Young and their colleagues [7,8]
suggested that the HTRA1 variant is more strongly associated
with the disease, Kanda and colleagues [6] suggested that
LOC387715/ARMS2 rather than the HTRA1 variants explain
the association of the chromosome 10q26 region with the
disease.  Since  the  variants  in  these  genes  are  in  almost
complete linkage disequilibrium in each of the populations
reported so far, additional functional studies are required to
determine which variant is involved in the pathogenesis of the
disease.
In that respect, conflicting evidence has been reported
regarding the functional significance of the HTRA1 promoter
variant. Yang and colleagues [7] observed that this variant is
associated with increased expression levels of the HTRA1
gene in 3 AMD patients homozygous to G allele of the HTRA1
promoter  variant  compared  with  3  control  patients
homozygous to the A wild-type allele. Dewan and colleagues
[8] described increased HTRA1 expression associated with the
promoter  variant.  These  authors  speculated  that  altered
HTRA1  expression  levels  might  be  involved  in  AMD.
However, Kanda and colleagues [6] suggested that the same
HTRA1 variant does not affect HTRA1 expression levels in
cell lines or in the retina. We have also failed to identify an
association between the HTRA1 variant and HTRA1 mRNA
levels in WBCs. Yet, this data does not preclude an effect of
the same promoter variant on retinal expression levels of
HTRA1 in the context of AMD.
It is still unclear which of the chromosome 10q26 variants
is involved in the pathogenesis of AMD. However, our data
show that additional genetic and environmental factors which
underlie  variable  phenotype  and  response  to  therapy  in
NVAMD are yet to be identified.
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